Faslodex and Bone loss - a phase IV clinical study of FDA data

Summary:

Bone loss is found among people who take Faslodex, especially for people who are female, 60+ old.

The phase IV clinical study analyzes which people take Faslodex and have Bone loss. It is created by eHealthMe based on reports of 18,008 people who have side effects when taking Faslodex from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 18, 2023

18,008 people reported to have side effects when taking Faslodex.
Among them, 83 people (0.46%) have Bone loss.

What is Faslodex?

Faslodex has active ingredients of fulvestrant. It is often used in breast cancer metastatic. eHealthMe is studying from 18,125 Faslodex users for its effectiveness, alternative drugs and more.

What is Bone loss?

Bone loss is found to be associated with 1,314 drugs and 552 conditions by eHealthMe.

Number of Faslodex and Bone loss reports submitted per year:

Gender of people who have Bone loss when taking Faslodex *:

female: 93.33 %
male: 6.67 %

Age of people who have Bone loss when taking Faslodex *:

Common drugs people take besides Faslodex *:

Common side effects people have besides Bone loss *:

Osteonecrosis Of Jaw (death of bone of jaw): 70 people, 84.34%
Pain: 66 people, 79.52%
Stress And Anxiety: 56 people, 67.47%
Back Pain: 56 people, 67.47%
Osteomyelitis (infection of bone): 47 people, 56.63%
Breathing Difficulty: 47 people, 56.63%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 45 people, 54.22%
Injury: 42 people, 50.60%
Fatigue (feeling of tiredness): 41 people, 49.40%
High Blood Pressure: 41 people, 49.40%

Common conditions people have *:

Metastases To Bone (cancer spreads to bone): 20 people, 24.10%
Osteoporosis (bones weak and more likely to break): 12 people, 14.46%
Diabetes: 8 people, 9.64%
Hypercalcaemia Of Malignancy (elevated calcium (ca+) level in the blood with cancer): 8 people, 9.64%
Depression: 8 people, 9.64%
Metastatic Neoplasm (spreadable cancer tumour): 7 people, 8.43%
Muscle Spasms (muscle contraction): 7 people, 8.43%
Hypercalcaemia (elevated calcium (ca+) level in the blood): 7 people, 8.43%
Nausea (feeling of having an urge to vomit): 7 people, 8.43%
Neoplasm Malignant (cancer tumour): 7 people, 8.43%

* Approximation only. Some reports may have incomplete information.

Do you take Faslodex and have Bone loss?

Check whether Bone loss is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Bone loss and when was it recovered:

Bone loss in Faslodex

Expand to all the drugs that have ingredients of fulvestrant:

Bone loss and drugs with ingredients of fulvestrant

Alternative drugs to, pros and cons of Faslodex:

Faslodex (18,125 reports)

Common Faslodex side effects:

Fatigue (feeling of tiredness): 3,308 reports
Pain: 1,828 reports
Weakness: 1,491 reports
Diarrhea: 1,436 reports
Death: 1,397 reports

Browse all side effects of Faslodex:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Bone loss treatments and more:

Bone loss (26,144 reports)

COVID vaccines that are related to Bone loss:

Common drugs associated with Bone loss:

All the drugs that are associated with Bone loss:

Bone loss (1,314 drugs)

Common conditions associated with Bone loss:

Hiv infection: 15,993 reports
Osteoporosis: 1,026 reports
Rheumatoid arthritis: 404 reports
Pain: 229 reports
High blood pressure: 210 reports
Osteoporosis post-menopausal: 170 reports
Gastroesophageal reflux disease: 162 reports
Multiple myeloma: 153 reports

All the conditions that are associated with Bone loss:

Bone loss (552 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on fulvestrant (the active ingredients of Faslodex) and Faslodex (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.